The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.
Aposense is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death).
The company was founded for the purpose of research and development of new therapies for the treatment of specific and hitherto incurable forms of leukaemia. Its business is the production, research and development of targeted pharmaceuticals based on nanoparticle structures.
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.
The company's Bioral drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a 'cochleate' cylinder. All of the components of the cochleate cylinder are naturally occurring substances. It is believed that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the selected drug.
Camurus specializes in the development of pharmaceuticals based on advanced and effective innovative nanoscale drug delivery systems that optimize the bioavailability and therapeutic performance of a wide range of difficult substances, including: peptides, proteins, and insoluble small molecules.
Commercializes a nano and micron sized ceramic spheres technology that provides encapsulation and controlled release of active molecules for a variety of applications including drug delivery, cosmeceuticals and speciality chemicals.
The group is involved in the rapidly developing field of nanobiopharmacy. It focuses on tissue engineering (e.g. scaffolds for cartilage and skin replacement, differentiation of stem cells into chondrocytes), wound healing, gene therapy and targeted drug delivery (using above mentioned polysaccharides and their conjugates). The research and innovation is an integral part of the company activities. Due to recent investments in the state-of-the art laboratory equipment and experienced and motivated scientists the company creates a unique center for regenerative medicine research, including various in-vitro and in-vivo tests.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
One of the company's delivery systems in the most advanced stages of clinical development is a novel drug delivery system for Paclitaxel. Because of the better safety and pharmacokinetic profile, the polymeric nanoparticle delivery system is seen as a potential super generic.